Takeda TAK NYSE · Healthcare · Japan
$21.80 +1.80% +$0.39
Summary
50 / 100 · Bulios Score
What speaks for it
- The price moves less than the market (beta 0.09).
What to watch
- The share price is above the Bulios Fair Price.
- Operating profit covers the interest on its debt only 2.3 times.
- It earns only 4.8 JPY a year on every 100 JPY of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 28.3 JPY for 1 JPY of yearly profit. Over the last five years it was 39.5 JPY on average.
Valuation in detailIs it growing?
SlowlyRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 7.1% a year over 5 years. Over the last 3 years it grew by 3.8% a year. For the next fiscal year analysts expect revenue to grow by 4.6%.
Growth in detailDoes it make money?
Very wellWhere 100 JPY of revenue goes
- Cost of sales 41 JPY
- Research and development 15 JPY
- Sales and administration 31 JPY
- Taxes and other 5.5 JPY
- Net profit 8.2 JPY
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 JPY
Out of every 100 JPY of revenue, 8.2 JPY is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 10.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 2.90%
- Paid out of profit
- 82%
- Raised in a row
- 1 year
You receive $0.62 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 5
- Hold 1
- Sell 0
No analyst has published a price target.
83% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Gastroenterology 31%
- PDT Immunology 23%
- Rare Diseases 17%
- Oncology 13%
- Neuroscience 9.2%
- Other 6.3%
By region
- UNITED STATES 49%
- Europe And Canada 26%
- JAPAN 9.8%
- Latin America 5.7%
- CHINA 4.4%
- Other 5.3%
Gastroenterology brings in 31% of revenue. PDT Immunology grew fastest, by 20% a year.
Segments in detail